FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 735 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Spotlight On: Pelvic Physical Therapists in Cancer Care March 31, 2021 Disparities in Cancer Care Between Citizens and Refugees in Lebanon March 23, 2021 Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... October 1, 2021 Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... May 8, 2021 Load more HOT NEWS For Childhood Eye Cancer, Researchers Investigating “Packaged” CAR T Cells Working to Make Cancer Clinical Trials More Inclusive: A Q&A With... FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated... Can Having Solar Panels or Living Near a Solar Farm Increase...
